SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2025-04-14 (juve-patent.com)
German Federal Patent Court upholds Xtandi patent in win for Astellas
Federal Patent Court upholds patent for prostate cancer drug in win for Xtandi Astellas and The Regents of the University of California.
Read more
2025-01-29 (juve-patent.com)
Another win for Astellas as Dutch court upholds Xtandi patent -
Astellas and Hoyng ROKH successfully defend formulation patent for Xtandi. The District Court The Hague dismissed Synthon's revocation claim.
Read more
2023-05-16 (elciudadanoweb.com)
San Lorenzo: ruling in favor of chemical workers of the multinational Synthon
There was a precautionary measure in favor of the union and they ask for its urgent compliance in the context of a conflict with the company that has been escalating since January
Read more
2017-10-26 (calcalistech.com)
Teva's Blockbuster Drug Takes Another Generic Blow
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
Read more
(globes.co.il)
Pfizer teams with Synthon on generic Copaxone -
Synthon has filed an application for a generic version of Teva's improved 40mg/mL dosage of the multiple sclerosis drug.
Read more
(bloomberglaw.com)
bristolmyers sues synthon to block copies of zeposia drug
Bristol-Myers Squibb Co. sued Netherlands-based Synthon BV alleging its proposed copies of Zeposia infringe a patent for the drug, used to treat ulcerative colitis and relapsing forms of multiple sclerosis.
Read more